Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
24 Feb 2017
Change (% chg)

$-0.07 (-3.93%)
Prev Close
$1.78
Open
$1.78
Day's High
$1.78
Day's Low
$1.69
Volume
29,404
Avg. Vol
34,499
52-wk High
$5.41
52-wk Low
$1.36

CYTX.OQ

Chart for CYTX.OQ

About

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused... (more)
No analyst recommendations are available for CYTX.OQ.

Overall

Beta: 2.35
Market Cap(Mil.): €33.40
Shares Outstanding(Mil.): 20.63
Dividend: --
Yield (%): --

Financials

  CYTX.OQ Industry Sector
P/E (TTM): -- 34.59 29.63
EPS (TTM): -8.34 -- --
ROI: -78.90 12.50 12.96
ROE: -286.17 14.56 14.11

BRIEF-Azaya Therapeutics Reports 5 pct passive stake in Cytori Therapeutics

* Azaya Therapeutics Inc reports 5 percent passive stake in Cytori Therapeutics as on Feb. 15, 2017 Source text:(http://bit.ly/2mg6n5N) Further company coverage:

Feb 24 2017

BRIEF-Cytori Therapeutics receives small business designation

* Cytori Therapeutics - FDA division of industry consumer education (DICE) has granted small business status to cytori therapeutics for fiscal year 2017 Source text for Eikon: Further company coverage:

Feb 06 2017

BRIEF-Cytori to acquire proprietary nanoparticle development platform

* Cytori to acquire proprietary nanoparticle development platform to enhance regenerative medicine leadership position

Jan 19 2017

BRIEF-Cytori to expand Scleroderma focus to its broader hand therapy franchise

* Cytori to expand scleroderma focus to broader hand therapy franchise under the habeo cell therapy brand

Jan 10 2017

BRIEF-Cytori announces 2-year follow-up published on EU scleroderma trial

* Cytori announces two year follow-up published on EU scleroderma trial Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Cytori granted FDA orphan drug designation for ECCS-50 in scleroderma

* Cytori granted FDA orphan drug designation for ECCS-50 in scleroderma Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Cytori Therapeutics Q3 loss per share $0.26

* Sees FY 2016 combined product and contract revenues anticipated to be within a range of $11 million to $13 million

Nov 09 2016

BRIEF-Cytori presents scleroderma clinical trial data at the 2016 American College Of Rheumatology annual meeting

* Cytori presents scleroderma clinical trial data at the 2016 American College of rheumatology annual meeting Source text for Eikon: Further company coverage:

Oct 26 2016

BRIEF-BARDA increases contract option with Cytori to advance Countermeasure Clinical Trial

* BARDA increases contract option with Cytori to advance countermeasure clinical trial

Sep 19 2016

More From Around the Web

Earnings vs. Estimates